These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1529 related articles for article (PubMed ID: 11221829)

  • 1. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment.
    Adamsen BL; Kravik KL; Clausen OP; De Angelis PM
    Int J Oncol; 2007 Dec; 31(6):1491-500. PubMed ID: 17982676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
    Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):231-3. PubMed ID: 15751639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
    Kusunoki M; Yanagi H; Noda M; Yoshikawa R; Yamamura T
    Cancer; 2000 Sep; 89(6):1228-35. PubMed ID: 11002217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
    Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
    Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
    Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
    Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
    Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
    Muneoka K; Shirai Y; Wakai T; Yokoyama N; Okumura S; Hatakeyama K
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):799-802. PubMed ID: 15984519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
    Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
    Suzuka I; Izumi S; Onoda Y; Shiota K; Nishihara M; Nakagawa J; Shimizu N
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2183-8. PubMed ID: 10635302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
    De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
    Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
    Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
    Yokoo H; Kamiyama T; Nakagawa T; Nakanishi K; Tahara M; Fukumori D; Kamachi H; Matsushita M; Todo S
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2400-3. PubMed ID: 20037436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
    Maruyama S; Maruyama M; Kato K; Koide A; Ohbu M; Hasegawa K; Takashima I; Ebuchi M
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1743-5. PubMed ID: 15553701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
    Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.